26Bile acids are metabolic links between hosts and their gut microbiomes, yet little is known about 27 the roles they play in microbe-to-microbe interactions. Here we present a study designed to 28 investigate the effect that a common probiotic, Lactobacillus acidophilus, has on microbial 29interactions that lead to formation of secondary bile acids. A model microbial consortium was 30 built from three human gut isolates, Clostridium scindens, Collinsella aerofaciens, and Blautia 31 obeum, and cultured under different bile acid and probiotic treatments. A multi-omics platform 32 that included mass spectrometry-based metabolomics and activity-based proteomic probes was 33 used to produce two major results. The first, was that an uncommon secondary bile acid -34 ursocholate -was produced by a multi-species chemical synthesis pathway. This result 35 highlights a new microbe-to-microbe interaction mediated by bile acids. The second finding was 36 that the probiotic strain, L. acidophilus, quenched the observed interactions and effectively 37 halted consortial synthesis of ursocholate. Little is known about the role that ursocholate plays in 38 human health and development. However, we did discover that a decrease in ursocholate 39 abundance corresponded with successful weight loss in patients after gastric bypass surgery 40 versus those who did not lose weight after surgery. Hence, this study uncovered basic knowledge 41 that may aid future designs of custom probiotic therapies to combat obesity. 42 43 44 Probiotic supplementation likely reduces the risk of developing antibiotic associated diarrhea 9 53 and necrotizing enterocolitis in infants 10 . However, the therapeutic opportunities for probiotics 54 are advancing to more precisely target specific processes carried out by the gut microbiome to 55 impart health benefits beyond enhanced digestion [11][12][13] . Probiotic therapies are being explored 56 relieve symptoms of autism 14 , depression 4 , autoimmune diseases 15,16 , and irritable bowel 57 syndrome 17 among many other conditions with positive -albeit conflicting -results. The 58 efficacy of probiotic treatments is variable. Differing results can obviously arise from 59 inconsistent study design -e.g., probiotic strain, dose -trial size, but they are also indicative of a 60 large scientific knowledge gap and incomplete understanding of the mechanisms by which 61 probiotics impact the GI-tract microbial ecosystem. 62There are many hypotheses about the modes of action by which the gut microbiome and 63 probiotic microbes impact human health. One proposed model is through modulation of the host 64 immune system 18 , which has been concluded from studies that showed probiotic treatments 65 affecting host immune function in humans facing pathogenic challenges [19][20][21] or with autoimmune 66 disorder 15,16,22 . Another hypothesis is that probiotics increase microbial competition within the 67 4 intestinal ecosystem, thereby making it more difficult for pathogenic bacteria to survive 23,24 . 68 Studies ...